GUCY2C and Parkinson disease: Our findings suggest that enhancing cyclic nucleotide signalling—whether via PDE inhibition or GUCY2C activation—holds considerable promise for treating Parkinson’s disease by boosting endogenous dopamine production through tyrosine hydroxylase Ser40 phosphorylation.